Detalhe da pesquisa
1.
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study.
Clin Infect Dis
; 76(3): e426-e438, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35607769
2.
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
Front Immunol
; 14: 1104124, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36776853
3.
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients.
Front Oncol
; 12: 855723, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35371993
4.
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Target Oncol
; 16(1): 59-68, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369704
5.
SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region.
Cancers (Basel)
; 13(5)2021 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33801186
6.
Lessons learned from COVID-19 for clinical research operations in Italy: what have we learned and what can we apply in the future?
Tumori
; 107(1): 6-11, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33297885
7.
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Cancer Treat Rev
; 40(1): 197-203, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23850197
8.
Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II.
J Thorac Oncol
; 7(7): 1124-30, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22610258